SLC5A2 and polycystic ovary syndrome: A recent small clinical trial demonstrated that administration of the SGLT2 inhibitor empagliflozin (EMPA) decreased body weight (BW), body mass index (BMI), and fat mass compared to metformin in PCOS women [11].